Business Wire

FOURKITES

1.9.2021 10:02:12 CEST | Business Wire | Press release

Share
FourKites Launches New Tools and Powerful Enhancements to Increase the Adoption of Supply Chain Visibility and Accelerate Time to Value

FourKites ® , the world’s leading real-time supply chain visibility platform , has released powerful new capabilities designed to help shippers, carriers and forwarders more quickly and easily collaborate to increase end customer satisfaction, reduce supply chain costs and increase on-time delivery performance. With ever-increasing demand, supply chain visibility has become table stakes for modern supply chains, and seamless connection and communication between carriers and shippers has never been more important. FourKites’ combination of swift carrier connections, powerful collaboration tools and the industry’s highest-quality real-time logistics data provides shippers and their forwarder/carrier partners with robust assurances of rapid, frictionless implementation and faster time to value.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005371/en/

  • Instant Messenger , now with extended capabilities that allow shippers to chat directly with forwarders and carriers, gives supply chain partners the ability to view and share important information and resolve issues together, in real time. Without leaving the FourKites platform, track-and-trace and dispatch workers, drivers and warehouse personnel can view the critical information that affects shipments and deliveries — all in one single interface. Users can share documents, photographs and notes for any given load, as well as form online workgroups and control access as needed.
  • CarrierLink ® , the industry’s most downloaded visibility app for drivers, now includes improved turn-by-turn navigation for better route optimisation; mobile check-in; and new capabilities for updating appointment times, adding notes to loads and uploading paperwork. It also features enhanced capabilities for viewing fuel stops, weigh stations, location ratings and amenities along routes.

"We have hundreds of carriers within our network, from the courier side to the truckload side. When it comes to onboarding, FourKites has been fantastic,” said Josh Dolan, VP of Global Logistics, Cardinal Health. “They've done a phenomenal job working with carriers through the process and helping us fill the gap with new technologies that simplify and speed up onboarding, and enhance communication between Cardinal Health and our partners."

The German multinational Bayer saves time while increasing customer satisfaction thanks to FourKites’ supply chain visibility platform. The impact has already been so strong that the company has made visibility an essential part of its long term strategy.

“Every day, our carriers automatically share location data with our FourKites platform on hundreds of loads throughout Europe,” says Edmund Jager, Head of Distribution EMEA at Bayer. “We are able to track our products minute by minute and, in real time, pass on detailed arrival times to our customers. This means the distributors we supply always know their stock situation and end customers can depend on us to get them the seeds and crop protection they need, when they need them. We look forward to onboarding more carriers and so strengthen our customer-centric approach.”

In addition, FourKites recently announced its industry-first Tracking Quality Guarantee , which establishes the highest standards in supply chain data, guaranteeing real-time visibility and predictive intelligence into a minimum of 90% of customers’ shipments — end-to-end and across every mode and geography. This differentiated approach gives supply chain partners the collaborative opportunities and network effects they need to improve customer satisfaction and optimise their supply chain performance.

“As the first mover and leading innovator in real-time visibility and supply chain management solutions, FourKites is committed to helping shippers, forwarders and carriers achieve end-to-end supply chain visibility faster, and with assurances of the highest-quality tracking in the industry,” said FourKites founder and CEO Mathew Elenjickal. “We are excited to make these powerful new capabilities available to the community to enable greater collaboration and communication, and ultimately, value.”

About FourKites

FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 600 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye